This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Exelixis (EXEL) announced results from the Phase 3 clinical trial of Cabometyx (cabozantinib) in treatment-experienced patients with hepatocellular carcinoma (‘HCC). The results were published in the New England Journal of Medicine (‘NEJM). Median overall survival (‘OS) showed statistically significant improvement over placebo. OS for Cabometyx was 10.2 months while that for placebo was 8 months. Median progression-free survival (‘PFS) too showed significant improvement.
KALTF EXEL KLH PRNAF NURO ISRG K CLVS JNJ SBOT PRAN PBT BMY
Exelixis, Inc. (EXEL - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $19.13 to $20.81 in the past one-month time frame.
EXEL DY ICHR GHDX
Shares of Exelixis have dropped over 34% since late February due to market overreaction, presenting a valuable long opportunity.
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription?
Nektar presented strong data during ASCO 2018. Nevertheless, investors were expecting something better. The shares tumbled over 40% for the day in the midst of its strong fundamentals.
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY
Exelixis recently posted negative data for the cobimetinib franchise, which caused the shares to tumble. Cobimetinib is simply an icing on the cake: cabozantinib is the key.
The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk tolerance. The first five picks are the top picks (in no particular order). Risks are increased the further away a stock sits from the middle (Picks #6, in the middle of the list, is the least risky).
SYBX MDGL VKTXW CCXI EXEL NVCR IMDZ VKTX HTGM
ScPharma (NASDAQ:SCPH) was part of almost every stock news column (including ours) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, but recovered a little and closed marginally higher at $8.92. Cumulatively, over the last few days the company slid from $14.22 to $8.
ZYME AMGN EXEL PETX INCY SRPT LLY NVLN SLS SCPH IONS CELG NVS
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.
SGEN NKTR ATRS BLCM VRTX NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE RDUS BMY CALD MOR EXEL GILD BLUE XNCR SLDB NBIX CRSP GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY
2018-02-15 - Asif
Exelixis is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX® (cabozantinib) tablets approved for previously treated advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer...
11h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to EXEL / Exelixis, Inc. on message board site Silicon Investor.
|Exelixis, Inc. (EXEL)||PRXL - Parexel International|
|NEXELL THE FASTEST GROWTH IN BIOTECHS NEXL|
as of ET